Characteristics of m = 1888 Cases With Symptom Onset Between June 15, 2020 and September 30, 2021, Who Were Tested by RT-PCR at Least Once Between 3 Weeks Before Symptom Onset and 5 Weeks After Onset
| Variable . | No. of Cases (m) . | % of Total Cases . |
|---|---|---|
| Sex | ||
| Female | 932 | 49.4% |
| Male | 955 | 50.6% |
| Unknown | 1 | 0.1% |
| Age (years) | ||
| 0–19 | 550 | 29.1% |
| 20–39 | 765 | 40.5% |
| 40–59 | 459 | 24.3% |
| 60–79 | 109 | 5.8% |
| ≥80 | 5 | 0.3% |
| Mean 31 (IQR, 17–44) | 1888 | 100% |
| Status | ||
| Confirmed | 1887 | 99.9% |
| Probable | 1 | 0.1% |
| Overseas-Acquired | ||
| Yes | 610 | 32.3% |
| No | 1271 | 67.3% |
| Unknown or NULL | 7 | 0.4% |
| Time Period (Variant) | ||
| Symptom onset between June 15, 2020 and June 30, 2021 (original strain or earlier variants of concern) | 670 | 35.5% |
| Symptom onset after July 1, 2021 (Delta variant) | 1218 | 64.5% |
| Comorbidities | ||
| At least 1 | 266 | 14.1% |
| None | 1622 | 85.9% |
| Vaccinated at Time of Diagnosis (at least 1 dose) | ||
| Yes | 242 | 12.8% |
| Noa | 1510 | 80.0% |
| Unknown | 136 | 7.2% |
| Ethnicity | ||
| Māori | 225 | 11.9% |
| Pacific Peoples | 844 | 44.7% |
| Non-Māori and non-Pacific (“Other”) | 811 | 43.0% |
| Unknown | 8 | 0.4% |
| Number of Tests | ||
| 1 | 1730 | 52.9% |
| 2 | 981 | 30.0% |
| 3 | 353 | 10.8% |
| 4 | 127 | 3.9% |
| 5 | 49 | 1.5% |
| ≥6 | 32 | 1.0% |
| Days From Symptom Onset to First Test | ||
| <−5 | 347 | 10.6% |
| −5 | 69 | 2.1% |
| −4 | 111 | 3.4% |
| −3 | 127 | 3.9% |
| −2 | 118 | 3.6% |
| −1 | 178 | 5.4% |
| 0 | 314 | 9.6% |
| 1 | 322 | 9.8% |
| 2 | 325 | 9.9% |
| 3 | 268 | 8.2% |
| 4 | 215 | 6.6% |
| 5 | 164 | 5.0% |
| 6 | 144 | 4.4% |
| 7 | 111 | 3.4% |
| 8 | 109 | 3.3% |
| 9 | 74 | 2.3% |
| ≥10 | 276 | 8.4% |
| Total | 1888 | |
| Variable . | No. of Cases (m) . | % of Total Cases . |
|---|---|---|
| Sex | ||
| Female | 932 | 49.4% |
| Male | 955 | 50.6% |
| Unknown | 1 | 0.1% |
| Age (years) | ||
| 0–19 | 550 | 29.1% |
| 20–39 | 765 | 40.5% |
| 40–59 | 459 | 24.3% |
| 60–79 | 109 | 5.8% |
| ≥80 | 5 | 0.3% |
| Mean 31 (IQR, 17–44) | 1888 | 100% |
| Status | ||
| Confirmed | 1887 | 99.9% |
| Probable | 1 | 0.1% |
| Overseas-Acquired | ||
| Yes | 610 | 32.3% |
| No | 1271 | 67.3% |
| Unknown or NULL | 7 | 0.4% |
| Time Period (Variant) | ||
| Symptom onset between June 15, 2020 and June 30, 2021 (original strain or earlier variants of concern) | 670 | 35.5% |
| Symptom onset after July 1, 2021 (Delta variant) | 1218 | 64.5% |
| Comorbidities | ||
| At least 1 | 266 | 14.1% |
| None | 1622 | 85.9% |
| Vaccinated at Time of Diagnosis (at least 1 dose) | ||
| Yes | 242 | 12.8% |
| Noa | 1510 | 80.0% |
| Unknown | 136 | 7.2% |
| Ethnicity | ||
| Māori | 225 | 11.9% |
| Pacific Peoples | 844 | 44.7% |
| Non-Māori and non-Pacific (“Other”) | 811 | 43.0% |
| Unknown | 8 | 0.4% |
| Number of Tests | ||
| 1 | 1730 | 52.9% |
| 2 | 981 | 30.0% |
| 3 | 353 | 10.8% |
| 4 | 127 | 3.9% |
| 5 | 49 | 1.5% |
| ≥6 | 32 | 1.0% |
| Days From Symptom Onset to First Test | ||
| <−5 | 347 | 10.6% |
| −5 | 69 | 2.1% |
| −4 | 111 | 3.4% |
| −3 | 127 | 3.9% |
| −2 | 118 | 3.6% |
| −1 | 178 | 5.4% |
| 0 | 314 | 9.6% |
| 1 | 322 | 9.8% |
| 2 | 325 | 9.9% |
| 3 | 268 | 8.2% |
| 4 | 215 | 6.6% |
| 5 | 164 | 5.0% |
| 6 | 144 | 4.4% |
| 7 | 111 | 3.4% |
| 8 | 109 | 3.3% |
| 9 | 74 | 2.3% |
| ≥10 | 276 | 8.4% |
| Total | 1888 | |
Abbreviations: IQR, interquartile range; RT-PCR, reverse transcription polymerase chain reaction.
Includes unvaccinated cases with value “not applicable” in the immunized field, eg, those tested before vaccinations became available in New Zealand or individuals aged under 16 who were ineligible for vaccination.
Characteristics of m = 1888 Cases With Symptom Onset Between June 15, 2020 and September 30, 2021, Who Were Tested by RT-PCR at Least Once Between 3 Weeks Before Symptom Onset and 5 Weeks After Onset
| Variable . | No. of Cases (m) . | % of Total Cases . |
|---|---|---|
| Sex | ||
| Female | 932 | 49.4% |
| Male | 955 | 50.6% |
| Unknown | 1 | 0.1% |
| Age (years) | ||
| 0–19 | 550 | 29.1% |
| 20–39 | 765 | 40.5% |
| 40–59 | 459 | 24.3% |
| 60–79 | 109 | 5.8% |
| ≥80 | 5 | 0.3% |
| Mean 31 (IQR, 17–44) | 1888 | 100% |
| Status | ||
| Confirmed | 1887 | 99.9% |
| Probable | 1 | 0.1% |
| Overseas-Acquired | ||
| Yes | 610 | 32.3% |
| No | 1271 | 67.3% |
| Unknown or NULL | 7 | 0.4% |
| Time Period (Variant) | ||
| Symptom onset between June 15, 2020 and June 30, 2021 (original strain or earlier variants of concern) | 670 | 35.5% |
| Symptom onset after July 1, 2021 (Delta variant) | 1218 | 64.5% |
| Comorbidities | ||
| At least 1 | 266 | 14.1% |
| None | 1622 | 85.9% |
| Vaccinated at Time of Diagnosis (at least 1 dose) | ||
| Yes | 242 | 12.8% |
| Noa | 1510 | 80.0% |
| Unknown | 136 | 7.2% |
| Ethnicity | ||
| Māori | 225 | 11.9% |
| Pacific Peoples | 844 | 44.7% |
| Non-Māori and non-Pacific (“Other”) | 811 | 43.0% |
| Unknown | 8 | 0.4% |
| Number of Tests | ||
| 1 | 1730 | 52.9% |
| 2 | 981 | 30.0% |
| 3 | 353 | 10.8% |
| 4 | 127 | 3.9% |
| 5 | 49 | 1.5% |
| ≥6 | 32 | 1.0% |
| Days From Symptom Onset to First Test | ||
| <−5 | 347 | 10.6% |
| −5 | 69 | 2.1% |
| −4 | 111 | 3.4% |
| −3 | 127 | 3.9% |
| −2 | 118 | 3.6% |
| −1 | 178 | 5.4% |
| 0 | 314 | 9.6% |
| 1 | 322 | 9.8% |
| 2 | 325 | 9.9% |
| 3 | 268 | 8.2% |
| 4 | 215 | 6.6% |
| 5 | 164 | 5.0% |
| 6 | 144 | 4.4% |
| 7 | 111 | 3.4% |
| 8 | 109 | 3.3% |
| 9 | 74 | 2.3% |
| ≥10 | 276 | 8.4% |
| Total | 1888 | |
| Variable . | No. of Cases (m) . | % of Total Cases . |
|---|---|---|
| Sex | ||
| Female | 932 | 49.4% |
| Male | 955 | 50.6% |
| Unknown | 1 | 0.1% |
| Age (years) | ||
| 0–19 | 550 | 29.1% |
| 20–39 | 765 | 40.5% |
| 40–59 | 459 | 24.3% |
| 60–79 | 109 | 5.8% |
| ≥80 | 5 | 0.3% |
| Mean 31 (IQR, 17–44) | 1888 | 100% |
| Status | ||
| Confirmed | 1887 | 99.9% |
| Probable | 1 | 0.1% |
| Overseas-Acquired | ||
| Yes | 610 | 32.3% |
| No | 1271 | 67.3% |
| Unknown or NULL | 7 | 0.4% |
| Time Period (Variant) | ||
| Symptom onset between June 15, 2020 and June 30, 2021 (original strain or earlier variants of concern) | 670 | 35.5% |
| Symptom onset after July 1, 2021 (Delta variant) | 1218 | 64.5% |
| Comorbidities | ||
| At least 1 | 266 | 14.1% |
| None | 1622 | 85.9% |
| Vaccinated at Time of Diagnosis (at least 1 dose) | ||
| Yes | 242 | 12.8% |
| Noa | 1510 | 80.0% |
| Unknown | 136 | 7.2% |
| Ethnicity | ||
| Māori | 225 | 11.9% |
| Pacific Peoples | 844 | 44.7% |
| Non-Māori and non-Pacific (“Other”) | 811 | 43.0% |
| Unknown | 8 | 0.4% |
| Number of Tests | ||
| 1 | 1730 | 52.9% |
| 2 | 981 | 30.0% |
| 3 | 353 | 10.8% |
| 4 | 127 | 3.9% |
| 5 | 49 | 1.5% |
| ≥6 | 32 | 1.0% |
| Days From Symptom Onset to First Test | ||
| <−5 | 347 | 10.6% |
| −5 | 69 | 2.1% |
| −4 | 111 | 3.4% |
| −3 | 127 | 3.9% |
| −2 | 118 | 3.6% |
| −1 | 178 | 5.4% |
| 0 | 314 | 9.6% |
| 1 | 322 | 9.8% |
| 2 | 325 | 9.9% |
| 3 | 268 | 8.2% |
| 4 | 215 | 6.6% |
| 5 | 164 | 5.0% |
| 6 | 144 | 4.4% |
| 7 | 111 | 3.4% |
| 8 | 109 | 3.3% |
| 9 | 74 | 2.3% |
| ≥10 | 276 | 8.4% |
| Total | 1888 | |
Abbreviations: IQR, interquartile range; RT-PCR, reverse transcription polymerase chain reaction.
Includes unvaccinated cases with value “not applicable” in the immunized field, eg, those tested before vaccinations became available in New Zealand or individuals aged under 16 who were ineligible for vaccination.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
